Navigation Links
Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention

CRANBURY, N.J., June 22, 2011 /PRNewswire/ -- The founders of Oncobiologics, Inc. today announced that the firm, a specialist in biologics proof-of-concept services, will launch itself to the biopharmaceutical industry at the 2011 BIO International Convention. The convention is being held June 27-30 at the Walter E. Washington Convention Center in Washington, DC.

Oncobiologics was founded by a group of leading scientists and engineers from top-tier global pharmaceutical and biotech companies, including Genentech, Eli Lilly, Bristol-Myers Squibb, Bayer, Merck, Johnson & Johnson, Schering-Plough and Medarex. The company is commercializing a new one-stop proof-of-concept "engine" that will enable biologic drug developers to economically and efficiently develop more of their pre-clinical drug candidates. Oncobiologics has raised start-up funding through U.S. government grants, bank loans, and investments by listed companies and private equity investors.

Oncobiologics founder and CEO Dr. Pankaj Mohan commented, "Oncobiologics was created to help unleash the tremendous wealth of pre-clinical assets generated by the U.S. biopharmaceutical industry. Historically, roughly 40% of those assets suffer significant delays due to capacity and financial constraints. Oncobiologics aims to deliver the world-class technical capabilities found at top-tier companies, with a cost structure that more closely resembles low-cost country outsourcing, thus easing this critical bottleneck."

Adds Mohan, "Our team sees a great business opportunity here, but we are equally committed to opening up the flow of promising drug candidates to the patient populations that so desperately need them."

The Oncobiologics business model features a core set of expert services that are supplemented by strategic partnerships with external industry specialists. Internal services include cell and molecular biology; and process, analytical and formulation development. Manufacturing services include stability studies; non-clinical manufacturing and QC testing, with clinical manufacturing commencing in 2012. Partner offerings include pre-clinical animal studies, immunogenicity studies, clinical study design and execution and regulatory affairs. Oncobiologics offers comprehensive turnkey proof-of-concept program outsourcing, or discrete projects to complement a client's internal development efforts.


Dr. Pankaj Mohan, Founder and CEO

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DNA Analyzer "Hello Truth" Unveiled During Innocence Network International Delegate Tour of DDC
2. Pharma ChemOutsourcing 2011 Unveils First Wave of 50 Biotech Chemist Speakers for September 12-15 Show in New Jersey
3. Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype
4. Cellectis Unveils Its New Corporate Website
5. Secrets of a chiral gold nanocluster unveiled
6. Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
7. iCyt Unveils New Flow Cytometry Products in Collaboration with Sony at CYTO2010
8. ClearTrial Unveils New Product Release at Partnerships in Clinical Trials Conference 2010
9. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
10. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
11. Brooks Instrument Unveils New Web site
Post Your Comments:
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... ... InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and ... as Chief Operating Officer. , Having joined InSphero in November 2013 as ... promoted to Head of InSphero Diagnostics in 2014. There she has built up ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
Breaking Biology Technology:
(Date:10/26/2015)... PUNE, India , October 26, ... --> --> ... Forecasts 2015 to 2021 as well ... Analysis 2015-2019 research reports to its ... . ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/23/2015)... and GOLETA, California , October 23, ... BIOPAC and SensoMotoric Instruments (SMI) announce a mobile plug ... data captured during interactive real-world tasks SensoMotoric ... integration of their established wearable solutions for eye tracking ... gaze behavior captured with SMI Eye Tracking Glasses ...
Breaking Biology News(10 mins):